
FIG. 1


Tumor volume
Tumor volume (mm3)
Days
Group 4: 8-701 50 mpk
Group 1: Control
Group 7: Delayed 8-701 50 mpk
Group 3: 8-701 30 mpk
Group 2: PD1
Group 9: CTLA4
Group 6: PD1 + 8-701 50 mpk
Group 8: PD1 + delayed 8-701 50 mpk
Group 5: PD1 + 8-701 30 mpk
Group 10: PD1 + CTLA4
Group 1: PBS (iv, biwk x 3)
Group 2: anti-PD1 RMP1-14 (5 mg/kg, ip, biwk x 2)
Group 3: BM2 (30 mg/kg, iv, biwk x 3)
Group 4: BM2 (50 mg/kg, iv, qwk x 3)
Group 5: anti-PD1 RMP1-14 (5 mg/kg, ip, biwk x 2), BM2 (30 mg/kg, iv, biwk x 3)
Group 6: anti-PD1 RMP1-14 (5 mg/kg, ip, biwk x 2), BM2 (50 mg/kg, iv, qwk x 3)
Group 7: BM2 (50 mg/kg, iv, qwk x 3 (start on day 8))
Group 8: anti-PD1 RMP1-14 (5 mg/kg, ip, biwk x 2), BM2 (50 mg/kg, iv, qwk x 3 (start on day 8))
Group 9: anti-CTLA4 9H10 (5 mg/kg, ip, day 1), anti-CTLA4 9H10 (2.5 mg/kg, ip, days 4,7)
Group 10: anti-CTLA4 9H10 (5 mg/kg, ip, day 1), anti-CTLA4 9H10 (2.5 mg/kg, ip, days 4,7), anti-PD1 RMP1-14 (5 mg/kg, ip, biwk x 2)



Anti-PD1 only
Anti-PD1/FGFR3 Combo
Optimal time for assessing immune infiltrate believed to be at 1-2 weeks post treatment initiation
Day of Study
Tumor Volume (mm3)

FIG. 2

FIG. 3




Lewis Lung Carcinoma
Tumor Volume (mm3)
2000
1500
1000
500
0
Vehicle n=4
8-701 n=4
Anti-PD-1 n=4
8-701 + Anti-PD-1 n=3
P<0.05 Tukey HSD
* sig diff vehicle
** sig diff all groups
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
Days

FIG. 4


Madison109
Vehicle n=3
B-701 n=4
Anti-PD-1 n=3
B-701 + Anti-PD-1 n=4
Tumor Volume (mm3)
4000
3500
3000
2500
2000
1500
1000
500
0
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
Days